Acetaminophen (Paracetamol) updated on 09-20-2024

Composite criterion: malformations of the genital system (cryptorchidism or hypospadias or clitoral hypertrophy or labial fusion, …)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18513
R79326
Zafeiri, 2022 Cryptorchidism (only males included) during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 0.87 [0.69;1.09] 107/12,354   357/54,866 464 12,354
ref
S18582
R79322
Fisher, 2016 Cryptorchidism (one or more testes not present in the inferior half of the scrotum for at least a few moments after manipulation) during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: No Paracetamol use: maternal ITW/questionnaires after pregnancy 0.97 [0.46;2.04] C 11/221   22/429 33 221
ref
S18599
R79327
Lind, 2013 Isolated Second- or Third-Degree Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires after pregnancy 0.90 [0.80;1.10] 895/3,402   568/2,366 1,463 3,402
ref
S18585
R79325
Snijder, 2012 Cryptorchidism (one or both testes were non-palpable, or when they could not be manipulated to a stable position in the scrotum) - Cumulative prevalence over 30 months follow up 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.38 [0.52;3.64] 5/-   -/- - -
ref
S18564
R79324
Kristensen, 2011 Congenital cryptorchidism during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.34 [0.70;2.55] 23/233   19/257 42 233
ref
S18596
R79323
Jensen, 2010 Diagnosis of cryptorchidism coded in accordance with the International Classification of Diseases 10 (ICD10 codes: Q53, Q531, Q531A, Q532, Q532A, and Q539) - Follow up between 6 and 13 years old throughout pregnancy prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.17 [0.94;1.46] 95/-   480/21,504 575 -
ref
S18505
R79328
Rebordosa a, 2008 Hypospadias 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy 1.01 [0.76;1.33] 80/26,424   181/61,718 261 26,424
ref
Total 7 studies 0.98 [0.88;1.08] 2,838 42,634
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Zafeiri, 2022Zafeiri, 2022 0.87[0.69; 1.09]46412,35420%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Fisher, 2016Fisher, 2016 0.97[0.46; 2.04]332212%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: criticalROB mesure: moderateROB reporting: critical Lind, 2013Lind, 2013 0.90[0.80; 1.10]1,4633,40240%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Snijder, 2012Snijder, 2012 1.38[0.52; 3.64]--1%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Kristensen, 2011Kristensen, 2011 1.34[0.70; 2.55]422332%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: critical Jensen, 2010Jensen, 2010 1.17[0.94; 1.46]575-21%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Rebordosa a, 2008Rebordosa a, 2008 1.01[0.76; 1.33]26126,42413%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (7 studies) I2 = 0% 0.98[0.88; 1.08]2,83842,6340.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.03[0.90; 1.17]1,37539,2320%NAZafeiri, 2022 Fisher, 2016 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 6 case control studiescase control studies 0.90[0.77; 1.06]1,4633,402 -NALind, 2013 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.98[0.88; 1.08]2,83842,6340%NAZafeiri, 2022 Fisher, 2016 Lind, 2013 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 7 Tags Adjustment   - No  - No 0.97[0.46; 2.04]33221 -NAFisher, 2016 1   - Yes  - Yes 0.98[0.87; 1.11]2,80542,41317%NAZafeiri, 2022 Lind, 2013 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 6 Paracetamol use   - maternal ITW/questionnaires after p ...  - maternal ITW/questionnaires after pregnancy 0.90[0.77; 1.06]1,4963,6230%NAFisher, 2016 Lind, 2013 2   - maternal ITW/questionnaires during ...  - maternal ITW/questionnaires during pregnancy 1.03[0.89; 1.19]1,34239,0119%NAZafeiri, 2022 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 5 All studiesAll studies 0.98[0.88; 1.08]2,83842,6340%NAZafeiri, 2022 Fisher, 2016 Lind, 2013 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 70.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.21.10.5960.000Zafeiri, 2022Fisher, 2016Lind, 2013Snijder, 2012Kristensen, 2011Jensen, 2010Rebordosa a, 2008

Asymetry test p-value = 0.2697 (by Egger's regression)

slope=-0.1341 (0.1007); intercept=0.9123 (0.7353); t=1.2408; p=0.2697

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.98[0.88; 1.08]2,83842,6340%NAZafeiri, 2022 Fisher, 2016 Lind, 2013 Snijder, 2012 Kristensen, 2011 Jensen, 2010 Rebordosa a, 2008 70.510.01.0